Diabetic Neuropathic Pain - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Diabetic Neuropathic Pain - Pipeline Review, H2 2016’, provides an overview of the Diabetic Neuropathic Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Neuropathic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Neuropathic Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathic Pain

The report reviews pipeline therapeutics for Diabetic Neuropathic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Diabetic Neuropathic Pain therapeutics and enlists all their major and minor projects

The report assesses Diabetic Neuropathic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Diabetic Neuropathic Pain

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathic Pain

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Diabetic Neuropathic Pain pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

APT Therapeutics, Inc.

Astellas Pharma Inc.

BioDelivery Sciences International, Inc.

Bristol-Myers Squibb Company

Centrexion Therapeutics Corp

Chromocell Corporation

Daiichi Sankyo Company, Limited

Grunenthal GmbH

Hydra ...

APT Therapeutics, Inc.

Astellas Pharma Inc.

BioDelivery Sciences International, Inc.

Bristol-Myers Squibb Company

Centrexion Therapeutics Corp

Chromocell Corporation

Daiichi Sankyo Company, Limited

Grunenthal GmbH

Hydra Biosciences, Inc.

Immune Pharmaceuticals Inc.

Laboratorios Del Dr. Esteve S.A.

Lohocla Research Corporation

Novaremed

PeriphaGen, Inc.

Pharmaleads SA

Prismic Pharmaceuticals, Inc.

Relmada Therapeutics, Inc.

Sphaera Pharma Pvt. Ltd.

Theravasc, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Diabetic Neuropathic ...

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Diabetic Neuropathic Pain Overview 9

Therapeutics Development 10

Pipeline Products for Diabetic Neuropathic Pain - Overview 10

Pipeline Products for Diabetic Neuropathic Pain - Comparative Analysis 11

Diabetic Neuropathic Pain - Therapeutics under Development by Companies 12

Diabetic Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes 14

Diabetic Neuropathic Pain - Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Diabetic Neuropathic Pain - Products under Development by Companies 18

Diabetic Neuropathic Pain - Products under Investigation by Universities/Institutes 19

Diabetic Neuropathic Pain - Companies Involved in Therapeutics Development 20

APT Therapeutics, Inc. 20

Astellas Pharma Inc. 21

BioDelivery Sciences International, Inc. 22

Bristol-Myers Squibb Company 23

Centrexion Therapeutics Corp 24

Chromocell Corporation 25

Daiichi Sankyo Company, Limited 26

Grunenthal GmbH 27

Hydra Biosciences, Inc. 28

Immune Pharmaceuticals Inc. 29

Laboratorios Del Dr. Esteve S.A. 30

Lohocla Research Corporation 31

Novaremed 32

PeriphaGen, Inc. 33

Pharmaleads SA 34

Prismic Pharmaceuticals, Inc. 35

Relmada Therapeutics, Inc. 36

Sphaera Pharma Pvt. Ltd. 37

Theravasc, Inc. 38

Diabetic Neuropathic Pain - Therapeutics Assessment 39

Assessment by Monotherapy Products 39

Assessment by Combination Products 40

Assessment by Target 41

Assessment by Mechanism of Action 43

Assessment by Route of Administration 45

Assessment by Molecule Type 47

Drug Profiles 49

(amitriptyline + ketamine hydrochloride) - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

(diclofenac sodium + triclocarban) - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

APT-102 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

AS-1069562 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

CC-8464 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

cebranopadol - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

clonidine hydrochloride - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

CNTX-6016 - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

EC-5026 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

filgrastim - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

GERP-001 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

HX-100 - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

Kindolor - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

mepivacaine hydrochloride - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

mirogabalin besylate - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

MR-309 - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

NRD-135SE1 - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

palmidrol - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

PGN-305 - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

PL-37 - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

Small Molecule to Activate Kv7.2 for Neuropathic Pain - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

sodium nitrite SR - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

Diabetic Neuropathic Pain - Dormant Projects 82

Diabetic Neuropathic Pain - Discontinued Products 85

Diabetic Neuropathic Pain - Product Development Milestones 87

Featured News & Press Releases 87

Mar 04, 2016: BioDelivery Sciences to provide an update on Clonidine Topical Gel at the Cowen And Company 36th Annual Healthcare Conference and the 28th Annual Roth Conference 87

Jan 06, 2016: Hydra Biosciences to Present at the 8th Annual Biotech Showcase Conference in San Francisco on Jan. 11 87

Sep 28, 2015: Pharmaleads Announces the Opening of French Sites in Its International Phase IIa Clinical Study of PL37 87

Apr 22, 2015: Pharmaleads Announces the Inclusion of the First Patient in Phase IIa Study of Oral PL37 for Pain in Diabetic Neuropathy 88

Mar 30, 2015: BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 89

Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin 90

Dec 08, 2014: BioDelivery Sciences Announces Completion of Randomization in Phase 3 Trial of Clonidine Topical Gel for the Treatment of Painful Diabetic Neuropathy 91

Aug 06, 2014: BioDelivery Sciences Provides Update on Ongoing Phase 3 Pivotal Trial for Clonidine Topical Gel for Painful Diabetic Neuropathy 91

Oct 30, 2012: Drug Offers New Pain Management Therapy For Diabetics, Study Finds 91

Jun 04, 2012: EpiCept Receives Scientific Advice From EMA For AmiKet CIPN Program 92

Appendix 94

Methodology 94

Coverage 94

Secondary Research 94

Primary Research 94

Expert Panel Validation 94

Contact Us 94

Disclaimer 95

List of Tables

List of Tables

Number of Products under Development for Diabetic Neuropathic Pain, H2 2016 10

Number of Products under Development for Diabetic Neuropathic Pain - ...

List of Tables

Number of Products under Development for Diabetic Neuropathic Pain, H2 2016 10

Number of Products under Development for Diabetic Neuropathic Pain - Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Development, H2 2016 17

Products under Development by Companies, H2 2016 18

Products under Investigation by Universities/Institutes, H2 2016 19

Diabetic Neuropathic Pain - Pipeline by APT Therapeutics, Inc., H2 2016 20

Diabetic Neuropathic Pain - Pipeline by Astellas Pharma Inc., H2 2016 21

Diabetic Neuropathic Pain - Pipeline by BioDelivery Sciences International, Inc., H2 2016 22

Diabetic Neuropathic Pain - Pipeline by Bristol-Myers Squibb Company, H2 2016 23

Diabetic Neuropathic Pain - Pipeline by Centrexion Therapeutics Corp, H2 2016 24

Diabetic Neuropathic Pain - Pipeline by Chromocell Corporation, H2 2016 25

Diabetic Neuropathic Pain - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 26

Diabetic Neuropathic Pain - Pipeline by Grunenthal GmbH, H2 2016 27

Diabetic Neuropathic Pain - Pipeline by Hydra Biosciences, Inc., H2 2016 28

Diabetic Neuropathic Pain - Pipeline by Immune Pharmaceuticals Inc., H2 2016 29

Diabetic Neuropathic Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2016 30

Diabetic Neuropathic Pain - Pipeline by Lohocla Research Corporation, H2 2016 31

Diabetic Neuropathic Pain - Pipeline by Novaremed, H2 2016 32

Diabetic Neuropathic Pain - Pipeline by PeriphaGen, Inc., H2 2016 33

Diabetic Neuropathic Pain - Pipeline by Pharmaleads SA, H2 2016 34

Diabetic Neuropathic Pain - Pipeline by Prismic Pharmaceuticals, Inc., H2 2016 35

Diabetic Neuropathic Pain - Pipeline by Relmada Therapeutics, Inc., H2 2016 36

Diabetic Neuropathic Pain - Pipeline by Sphaera Pharma Pvt. Ltd., H2 2016 37

Diabetic Neuropathic Pain - Pipeline by Theravasc, Inc., H2 2016 38

Assessment by Monotherapy Products, H2 2016 39

Assessment by Combination Products, H2 2016 40

Number of Products by Stage and Target, H2 2016 42

Number of Products by Stage and Mechanism of Action, H2 2016 44

Number of Products by Stage and Route of Administration, H2 2016 46

Number of Products by Stage and Molecule Type, H2 2016 48

Diabetic Neuropathic Pain - Dormant Projects, H2 2016 82

Diabetic Neuropathic Pain - Dormant Projects (Contd..1), H2 2016 83

Diabetic Neuropathic Pain - Dormant Projects (Contd..2), H2 2016 84

Diabetic Neuropathic Pain - Discontinued Products, H2 2016 85

Diabetic Neuropathic Pain - Discontinued Products (Contd..1), H2 2016 86

List of Figures

List of Figures

Number of Products under Development for Diabetic Neuropathic Pain, H2 2016 10

Number of Products under Development for Diabetic Neuropathic Pain - ...

List of Figures

Number of Products under Development for Diabetic Neuropathic Pain, H2 2016 10

Number of Products under Development for Diabetic Neuropathic Pain - Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Products, H2 2016 17

Assessment by Monotherapy Products, H2 2016 39

Number of Products by Top 10 Targets, H2 2016 41

Number of Products by Stage and Top 10 Targets, H2 2016 41

Number of Products by Top 10 Mechanism of Actions, H2 2016 43

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 43

Number of Products by Routes of Administration, H2 2016 45

Number of Products by Stage and Routes of Administration, H2 2016 45

Number of Products by Molecule Types, H2 2016 47

Number of Products by Stage and Molecule Types, H2 2016 47

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports